PAK1 is a serine/threonine protein kinase involved in cytoskeletal signaling and oncogenic transformation. The dysregulation of PAK1 has been reported in breast, squamous NSCLC, and pancreatic cancers. NVS-PAK1-1 is a potent, selective, allosteric PAK1 Inhibitor with an IC50 value of 5nM. It has a biochemical PAK1 Kd of 7nM and a PAK2 Kd of 400nM. NVS-PAK1-1 significantly inhibited pMEK Ser289 at a concentration of 6–20μM. It inhibited the proliferation of Su86.86 cells at a concentration of 2μM. NVS-PAK1-1 at 0.21μM also significantly inhibited downstream signaling and cell proliferation when applied together with PAK2 shRNA. NVS-PAK1-1 exhibited high Caco2 permeability (Papp A-B 42.8 × 10-8cm/s). NVS-PAK1-1 showed a relatively poor stability in rat liver microsomes (t1/2=3.5min)[2].
NVS-PAK1-1 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
Balb/c nude mice
MCF7-PAK1 xenograft models
Oral gavage, p.o.
15 mg/kg
Daily for 15 days
Significantly prevented tumor growth
NPJ Breast Cancer. 2023 May 31;9(1):48
Mice
Nf2-cKO genetically engineered Mice model
Oral gavage
30 mg/kg NVS-PAK1-1 + 100 mg/kg 1-ABT
Once daily for 12 weeks
Evaluate the inhibitory effect of NVS-PAK1-1 on tumor growth, results showed a statistically significant reduction in average DRG volume
搜索
